AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05122676 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: More Individualized Care: Assessment and Recovery through Engagement (MI-CARE)
Description: This study evaluates whether offering nurse collaborative care management for 12 months by telephone or video can improve depression-related symptoms, increase access to evidence-based medication treatment for opioid use problems, as well as decreasing adverse health events. Participants randomized to the nurse support arm can work with the nurse at no cost for up to 12 months via phone or video visits.~The nurse asks questions about stress, mood, worry, pain, sleep, and medication and substance use; participants choose what to focus on. The nurse meets weekly with clinical consultants who may recommend treatment options, tailored to the patient. The participant and their regular provider(s) can discuss the options and decide which to try. The nurse and primary care provider can then help the patient access selected options. The nurse can also offer behavioral activation to help build skills to increase day-to-day positive adaptive experiences and support broader treatment gains.
Study NCT05280704 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Volar digital block with lidocaine
Description: Volar digital block with lidocaine
Study NCT06675201 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: neoantigen-loaded dendritic cell vaccine (NeoDC-Vac)
Description: Experimental Group: Neoantigen Vaccine Combined with Immune Checkpoint Inhibitors (ICIs) Neoantigen Vaccine: Administered via subcutaneous injections at multiple sites, including bilateral axillary and bilateral inguinal regions. The initial phase consists of 5 injections during the first cycle, given at weeks 1, 2, 4, 6, and 8. Thereafter, the vaccine is administered once every 4 weeks, continuing for 1 year, or until disease progression, intolerable adverse events, or death from any cause.~ICIs: Administered intravenously once a month, with a maintenance duration of 1 year, or until disease progression, intolerable adverse events, or death from any cause.~Control Group: ICIs ICIs: Administered intravenously once a month, with a maintenance duration of 1 year, or until disease progression, intolerable adverse events, or death from any cause.
Study NCT06675201 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: neoantigen-loaded dendritic cell vaccine (NeoDC-Vac)
Description: Experimental Group: Neoantigen Vaccine Combined with Immune Checkpoint Inhibitors (ICIs) Neoantigen Vaccine: Administered via subcutaneous injections at multiple sites, including bilateral axillary and bilateral inguinal regions. The initial phase consists of 5 injections during the first cycle, given at weeks 1, 2, 4, 6, and 8. Thereafter, the vaccine is administered once every 4 weeks, continuing for 1 year, or until disease progression, intolerable adverse events, or death from any cause.~ICIs: Administered intravenously once a month, with a maintenance duration of 1 year, or until disease progression, intolerable adverse events, or death from any cause.~Control Group: ICIs ICIs: Administered intravenously once a month, with a maintenance duration of 1 year, or until disease progression, intolerable adverse events, or death from any cause.
Study NCT06675578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tulsi gel
Description: After scaling and root debridement, 4% of Tulsi gel will be injected in to the sulcus until it over flooded, at base line, then after one month.
Study NCT06675578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gel
Description: After scaling and root debridement, 1% of Chlorhexidine gel will be injected in to the sulcus until it over flooded, at base line, then after one month.
Study NCT05280704 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Volar digital block with saline
Description: Volar digital block with saline
Study NCT03570879 — intervention group
Intervention type: DEVICE
Intervention: Power morcellation
Description: Power morcellation of surgical specimens after laparoscopic myomectomy.
Study NCT03570879 — intervention group
Intervention type: PROCEDURE
Intervention: Transvaginal extraction
Description: Transvaginal extraction of surgical specimens after laparoscopic myomectomy.
Study NCT06256757 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fenestration
Description: Thoracic EndoVascular Aortic Repair (TEVAR) with fenestrations
Study NCT06256757 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: fenestration
Description: Thoracic EndoVascular Aortic Repair (TEVAR) with fenestrations
Study NCT04628663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Administration
Study NCT04628663 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Administration
Study NCT04793633 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: LINFU™ Technique
Description: Non-focused ultrasound excitation of the pancreas with IV Lumason and IV secretin injected during the ultrasound procedure.
Study NCT05284552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinzaparin Injectable Solution
Description: Subcutaneous injection
Study NCT06675617 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Allay Aortic Stent
Description: Endovascular treatment of an aortic dissection
Study NCT06526520 — intervention group
Intervention type: DRUG
Intervention: Exposure to progesterone or HRT medication
Description: to add either progesterone only in the NPP protocol or E2 and progesterone in a HRT protocol
Study NCT06678854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training about Aphasia
Description: Training will include direct teaching, aphasia simulations, scenario-based training and a panel with persons with aphasia with the goal of increasing confidence for law enforcement officers and first responders providing services to and communicating with persons with aphasia.
Study NCT05676073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHEN26 dose 1
Description: Specification: 200mg/capsule. Subjects will receive 10 oral doses twice daily (after breakfast and dinner; Q12h±2h) from Day 1 to Day 5 (or Day 1 to Day 6).
Study NCT05676073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHEN26 dose 2
Description: Specification: 400mg/capsule. Subjects will receive 10 oral doses twice daily (after breakfast and dinner; Q12h±2h) from Day 1 to Day 5 (or Day 1 to Day 6).
Study NCT05676073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHEN26 placebo
Description: Placebo matching the SHEN26 capsule. Subjects will receive 10 oral doses twice daily (after breakfast and dinner; Q12h±2h) from Day 1 to Day 5 (or Day 1 to Day 6).
Study NCT06526728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Description: Participants will be subjected to seven once-daily sessions of hyperbaric oxygen therapy. Each session will last 115-120 minutes whereby the chambre will be pressurized to 2.4 ATA during which participants will breathe 100% (pure) oxygen.
Study NCT03660072 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study NCT05013723 — intervention group
Intervention type: OTHER
Intervention: Surveys
Description: Mental health validated psychometric surveys: Depression (PHQ-9), Anxiety (GAD-7), PTSD (PC-PTSD-5) Quality of Life surveys: Post COVID-19 Function Status Scale, Quality of life (SF-12)
Study NCT04327310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meplazumab for Injection
Description: humanized mAb against CD147
Study NCT04327310 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile normal saline (0.9%)
Description: Sterile normal saline (0.9%)
Study NCT05280704 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dorsal digital block with lidocaine
Description: Dorsal digital block with lidocaine
Study NCT05895773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine
Description: Povidone Iodine 0.5% plus glycyrrhizin acid 2.5 mg/ml as a nasal and an oropharyngeal spray (mint flavored) will be applied 4 times per day.
Study NCT05895773 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline spray
Description: Normal saline 0.9% as a nasal and oropharyngeal spray (Mint flavored) will be applied 4 times per day.
Study NCT05280704 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dorsal digital block with saline
Description: Dorsal digital block with saline
Study NCT05243056 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive enhanced usual care
Study NCT05243056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive Y-AMBIENT
Study NCT05243056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05319600 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes behavior change skills training
Description: Behavior-change skills training will be provided through eight web-delivered content and activity sessions across the 12-week program. Sessions 1 through 4 will occur weekly and sessions 5 through 8 biweekly. Each session takes approximately 15-20 minutes for the adolescent to complete both content learning and related activities. These learning sessions focus on skills like problem solving and goal setting.
Study NCT05319600 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity promotion program
Description: The physical activity incentives program includes 12 weeks of personalized goals and incentives for increasing physically active minutes along with weekday text-based support. Active minutes, defined as minutes with moderate to vigorous physical activity, will be tracked via a Garmin fitness activity tracker.
Study NCT06193902 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LEU011
Description: Immunotherapy
Study NCT05998408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Subjects will be instructed to take ruxolitinib at up to 20mg (total) BID for up to 6 months (with or without food)
Study NCT05243056 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05243056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06476808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986463
Description: Specified dose on specified days
Study NCT06488547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing (DF)
Description: Diaphragmatic breathing (DF), also known as belly or abdominal breathing, is a technique that can teach people how to use their diaphragm correctly while breathing, in order to activate the parasympathetic branch of the autonomic nervous system and to control stress.
Study NCT06488547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Description: Progressive Muscle Relaxation (PMR) is a technique that is helpful in the reduction of stress.~PMR by alternately tensing and relaxing different muscle groups in the body helps participants to become more aware of physical sensations and can be particularly helpful to muscle tension and relaxation.
Study NCT05243056 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06675682 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot Juice (Beet-It Stamina Shot) and Exercise Training
Description: Player randomization was performed using an online tool (https://www.randomizer.org/). An independent researcher assigned alphanumeric codes to each sequence to ensure blinding of both sprint athletes and researchers during the trials. Each player participated in two identical experimental trials separated by one week to allow physical recovery between testing occasions and washout from the beetroot juice treatment.
Study NCT06675682 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot Juice (Beet-It Stamina Shot) and Exercise Training
Description: Player randomization was performed using an online tool (https://www.randomizer.org/). An independent researcher assigned alphanumeric codes to each sequence to ensure blinding of both sprint athletes and researchers during the trials. Each player participated in two identical experimental trials separated by one week to allow physical recovery between testing occasions and washout from the beetroot juice treatment.
Study NCT06057948 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OPT-821 (QS-21)
Description: Comprised of the immunological adjuvant OPT-821 (QS-21)
Study NCT06057948 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral β-glucan
Description: Participants will be randomized to receive this agent in two different schedules
Study NCT06674434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilization with Movement
Description: Mobilization with Movement (MWM) is a manual therapy technique that combines active, patient-directed movements with passive joint mobilization to treat tennis elbow. To find joint restrictions or dysfunctions, a comprehensive patient assessment is the first step in the process. While the patient was in a supine position with the elbow fully extended and the forearm pronated, the therapist applied a sustained lateral glide of the forearm and stabilized the distal portion of the arm. While the patient asked to make a fist, the therapist kept up the lateral glide. Each session included three sets of movement-based mobilizations, each with ten repetitions. The entire course of treatment consists of twelve sessions.
Study NCT06674434 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sustained Stretch
Description: The basic concept of stretching involves lengthening the tendon during a state of relaxation. To stretch the Extensor Carpi Radialis Brevis tendon, the following position should be adopted: the elbow should be extended, the forearm in a pronated position, the wrist flexed, and the wrist should also be ulnar deviated, based on the patient's comfort level. This position should be maintained for 30 to 45 seconds and repeated three times before and after exercises in each treatment session, with a 30-second rest period in between.
Study NCT06674590 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation
Description: PNF of 30 minutes duration will given in a single session. Pelvic anterior elevation and posterior depression of the hemiplegic side. rhythmic initiation slow reversal agonistic reversals Pelvic anterior depression and posterior elevation of the hemiplegic side. The first diagonal (D1): Flexion and extension The second diagonal (D2): Flexion and extension 4 session per week
Study NCT05041530 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REBUILD Bioabsorbable
Description: REBUILD is an investigational medical device designed to be used with third-party suture to distribute suture tension in abdominal wall closures.
Study NCT05030376 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: intraileal infusion
Description: intraileal glucose or intraileal saline infusion
Study NCT05037370 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wave-Front Optimized (WFO) ablation vs Topography-guided (TG) ablation
Description: Patient will undergo PRK or LASIK using WFO ablation in one eye and TG ablation on contralateral eye
Study NCT05901792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Games
Description: Six different Nintendo Wii Fit Plus games will be employed for six weeks, three days a week, for a total of 18 sessions ranging from 40 to 60 minutes. The games will be chosen from those that emphasize shifting the body's center of gravity. In addition, participants will be given basic correction exercises (derotation, deflexion, basic tension, and lateral flexion 3\*3) at the beginning of the study and instructed to practice them at home for six weeks.
Study NCT05901792 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waiting List
Description: As the control group, the cases on the waiting list will be evaluated. The control group will be given basic elements of corrective exercises (derotation, deflexion, basic tension, and lateral flexion 3\*3) at the start of the study and instructed to practice at home for six weeks.
Study NCT05741411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RPM-assisted specialist access
Description: Participants will be prompted to report current symptoms and activity once a day via remote patient monitoring chat technology for up to 28 days following injury. Patients with either escalating or plateauing symptoms will be flagged, with an electronic alert sent via the electronic health record to a nurse navigator. The nurse navigator will have access to the symptom data and facilitate scheduling an in person or telehealth specialist visit as indicated. Symptoms will continue to be monitored through the 28-day acute study period with additional clinical visits occurring according to clinical need.
Study NCT05893043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSBR-1290
Description: Participants will receive GSBR-1290 oral capsules.
Study NCT05893043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo oral capsules.
Study NCT05755191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEU-411
Description: Oral Doses
Study NCT05755191 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Doses
Study NCT05037903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Description: Cognitive and behavioral interventions aimed at increasing behavioral activation, and reducing procrastination and inattentive symptoms.
Study NCT05049525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole 400 mg/day and terbinafine 500 mg/day administered orally.
Description: Itraconazole capsules of 100 mg, antifungal agent. Terbinafine tablets 250 mg (as terbinafine hydrochloride), antifungal agent.
Study NCT05049525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Itraconazole's matching placebo 400 mg/day and terbinafine's matching placebo 500 mg/day administered orally.
Description: Matching placebo of itraconazole capsules of 100 mg, antifungal agent. Matching placebo of terbinafine tablets 250 mg, antifungal agent.
Study NCT06674590 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Motor Relearning Program
Description: Motor Relearning Programme (MRP) This is a task-oriented approach to help the control of movement, focusing on the relearning of daily activities.
Study NCT05585164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engage & Connect (E&C)
Description: Engage \& Connect, is a remotely-delivered extension of Engage psychotherapy. It is aimed to increase engagement in rewarding social activities and in turn, reduce postpartum depression. In each session, the therapist will work with the patient to develop action plans to pursue rewarding social activities of their choice with the goal of reducing social isolation.
Study NCT05585164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom Review and Psychoeducation (SRP)
Description: SPR is a remotely-delivered intervention aimed to increase knowledge of postpartum depression and monitor mental health changes. In each session, the therapist will review the participant's symptoms and discuss information related to postpartum depression and changes after birth.
Study NCT06675851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline
Description: Bupropion 150 mg daily after baseline PET/MRI or MRI/MRS over 6-8 weeks
Study NCT06675851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cipralex (escitalopram)
Description: Escitalopram 10 mg daily after baseline PET/MRI or MRI/MRS over 6-8 weeks
Study NCT06681012 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gelsectan®
Description: Oral capsules are to be taken twice a day for 2 months (two capsules in the morning before breakfast and two capsules in the evening before dinner during the first 4 weeks of treatment; one capsule in the morning and one in the evening during the following 4 weeks of treatment).
Study NCT04990882 — intervention group
Intervention type: OTHER
Intervention: Interpretation of FAPI-PET/CT scans
Description: Each observer's Group will be asked to review FAPI-PET/CT scans of patients with representative cancer types.
Study NCT05778760 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Retinol
Description: Topical retinol (0.5%) applied to the face
Study NCT05778760 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapinoid
Description: Topical Adapinoid (0.5%) applied to the face
Study NCT05659680 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WiSE-CRT
Description: Participants undergo pre-procedural CT, implantation of the WiSE-CRT system targeting the left bundle branch area, and post procedural non-invasive electro-anatomical mapping using electrocardiographic imaging and haemodynamic assessment.
Study NCT06278961 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Observation of movement patterns through video recordings and neurodevelopmental battery of assessments.
Study NCT06206044 — intervention group
Intervention type: DRUG
Intervention: Intrathecal 1.6 ml 0.75% bupivacaine in 8.25% dextrose combined with 15 mcg fentanyl and 150 mcg preservative-free morphine
Description: Patients will receive standard intrathecal medications for urgent and scheduled cesarean delivery at the study site. All study subjects will receive bupivacaine, fentanyl, and morphine.